Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Tacrolimus rescue therapy for renal allograft rejection - Five-year experience

Jordan, ML and Naraghi, R and Shapiro, R and Smith, D and Vivas, CA and Scantlebury, VP and Gritsch, HA and McCauley, J and Randhawa, P and Demetris, AJ and McMichael, J and Fung, JJ and Starzl, TE (1997) Tacrolimus rescue therapy for renal allograft rejection - Five-year experience. Transplantation, 63 (2). 223 - 228. ISSN 0041-1337

Accepted Version
Available under License : See the attached license file.

Download (1MB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)


Over the 5 year period from 7/14/1989 until 5/24/1994, we have attempted graft salvage with tacrolimus conversion in a total of 169 patients (median age 33 years, range 2-75 years) with ongoing rejection on baseline CsA immunosuppression after failure of high dose corticosteroids and/or antilymphocyte preparations to reverse rejection. The indications for conversion to tacrolimus were ongoing, biopsy confirmed rejection in all patients. The median interval to tacrolimus conversion was 2 months (range 2 days to 55 months; mean 4.3±2.6 months) after transplantation. All patients had failed high dose corticosteroid therapy and 144 (85%) of the 169 patients had received at least one course of an antilymphocyte preparation plus high dose corticosteroid therapy prior to conversion. Twenty-eight patients (17%) were dialysis-dependent at the time of conversion owing to the severity of rejection. With a mean follow-up of 30.0±2.4 months (median 36.5 months, range 12-62 months), 125 of 169 patients (74%) have been successfully rescued and still have functioning grafts with a mean serum creatinine (SCR) of 2.3±1.1 mg/dl. Of the 144 patients previously treated with antilymphocyte preparations, 117 (81%) were salvaged. Of the 28 patients on dialysis at the time of conversion to tacrolimus, 13 (46%) continue to have functioning grafts (mean SCR 2.15±0.37 mg/dl) at a mean follow-up of 37.3±16.7 months. In the 125 patients salvaged, prednisone doses have been lowered from 28.0±9.0 mg/d (median 32, range 4-60 mg/d) preconversion to 8.5±4.1 mg/d (median 12 mg/d, range 2.5-20 mg/d) postconversion. Twenty-eight patients (22.4%) are currently receiving no steroids. This 5 year experience demonstrates that tacrolimus has sustained efficacy as a rescue agent for ongoing renal allograft rejection. Based on these data, we recommend that tacrolimus be used as an alternative to the conventional drugs used for antirejection therapy in renal transplantation.


Social Networking:
Share |


Item Type: Article
Status: Published
CreatorsEmailPitt UsernameORCID
Jordan, ML
Naraghi, R
Shapiro, R
Smith, D
Vivas, CA
Scantlebury, VP
Gritsch, HA
McCauley, J
Randhawa, P
Demetris, AJ
McMichael, J
Fung, JJ
Starzl, TEtes11@pitt.eduTES11
Centers: Other Centers, Institutes, Offices, or Units > Thomas E. Starzl Transplantation Institute
Date: 27 January 1997
Date Type: Publication
Journal or Publication Title: Transplantation
Volume: 63
Number: 2
Page Range: 223 - 228
DOI or Unique Handle: 10.1097/00007890-199701270-00008
Institution: University of Pittsburgh
Refereed: Yes
ISSN: 0041-1337
Other ID: uls-drl:31735062134238, Starzl CV No. 1966
Date Deposited: 08 Apr 2010 17:33
Last Modified: 27 Jan 2019 02:55


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item